$2.96
▲ +$0.28
(+10.45%)
Vol 2.1M
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$210.8M
ROE
-107.1%
D/E
15.88
Beta
3.27
52W
$1–$4
Wall Street Consensus
16 analysts · Apr 20266
Strong Buy
7
Buy
3
Hold
0
Sell
0
Strong Sell
81.2%
Buy Rating
Price Chart
Similar Stocks
IVVD
Invivyd Inc
$684.5M
IMRX
Immuneering Corp
$424.9M
PBYI
Puma Biotechnology Inc
P/E 8.1
$299.8M
DMAC
DiaMedica Therapeutics Inc
$414.5M
XOMA
Xoma Royalty Corp
P/E 15.2
$329.3M
IRD
Opus Genetics Inc
$138.6M
XFOR
X4 Pharmaceuticals Inc
$349.7M
NGNE
Neurogene Inc
$319.1M
FBRX
Forte Biosciences Inc
$341.6M
SRZN
Surrozen Inc
$193.7M
Earnings
Beat rate: 40.0%
Next Report
May 13, 2026
EPS Estimate: $-0.41
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.41 | — | — |
| Dec 2025 | $-0.47 | $-0.40 | +$0.07 |
| Sep 2025 | $-0.48 | $-0.44 | +$0.04 |
| Jun 2025 | $-0.66 | $-0.73 | $-0.07 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -$30.6M | -$32.6M | -$35.9M | -$45.1M | -$44.9M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -92.1% | -92.1% | -92.1% | -92.1% | -107.1% | -107.1% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 11.39 | 11.39 | 11.39 | 11.39 | 15.88 | 15.88 |
| Current Ratio | 4.78 | 4.78 | 4.78 | 4.78 | 3.60 | 3.60 |
Key Ratios
ROA (TTM)
-83.0%
P/B
0.7
EPS (TTM)
$-2.51
CF/Share
$-1.64
52W High
$3.67
52W Low
$0.99
$0.99
52-Week Range
$3.67
Financial Health
Free Cash Flow
-$34.6M
Net Debt
-$34.4M
Cash
$60.2M
Total Debt
$25.8M
As of Sep 30, 2025
How does CABA compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
CABA valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
0.7
▼
70%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
CABA profitability vs Biotechnology peers
ROE
-107.1%
▼
59%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
—
▼
0%
below
peers
(-286.8%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-83.0%
▼
78%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
CABA financial health vs Biotechnology peers
D/E ratio
15.9
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
3.6
▼
19%
below
peers
(4.4)
vs Peers
vs Industry
Below avg
Beta
3.3
▲
237%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
CABA fundamentals radar
CABA
Peer median
Industry
CABA profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
CABA vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
SIMON MARK
Director · Jan 21
11061 shs
NICHTBERGER STEVEN
Chief Executive Officer · Jan 21
45000 shs
TOMASELLO SHAWN CLINE
Director · Jan 21
22725 shs
CHANG DAVID J. M.D.
Officer · Jan 21
8800 shs
BOLLARD CATHERINE M.D.
Director · Jan 21
4405 shs
BINDER GWENDOLYN
Officer · Jan 21
11312 shs
GERARD MICHAEL
General Counsel · Jan 21
6600 shs
GAVEL STEVE
Officer · Jan 21
22170 shs
Last 90 days
Top Holders
Top 5: 43.3%T. Rowe Price Investment Ma…
10.24%
$26.4M
Bain Capital Life Sciences …
10.05%
$25.9M
Jennison Associates LLC
9.25%
$23.9M
Adage Capital Partners GP L…
9.17%
$23.7M
Vanguard Group Inc
4.59%
$11.8M
As of Dec 31, 2025
Latest News
No related news yet